S2k‐Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids
2015; Wiley; Volume: 13; Issue: 7 Linguagem: Alemão
10.1111/ddg.40_12612
ISSN1610-0387
AutoresEnno Schmidt, Matthias Goebeler, Michael Hertl, Miklós Sárdy, Cassian Sitaru, Rüdiger Eming, Silke Hofmann, Nicolas Hunzelmann, Johannes S. Kern, Harald Kramer, Hans‐Dieter Orzechowski, Christiane Pfeiffer, Volker Schuster, Birte Sporbeck, Michael Sticherling, Margitta Worm, Detlef Zillikens, Alexander Nast,
Tópico(s)Platelet Disorders and Treatments
ResumoJDDG: Journal der Deutschen Dermatologischen GesellschaftVolume 13, Issue 7 p. 713-727 Leitlinien S2k-Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids Enno Schmidt, Corresponding Author Enno Schmidt Klinik für Dermatologie, Allergologie und Venerologie, Universität Lübeck, Lübeck Korrespondenzanschrift Prof. Dr. med. Dr. rer. nat. Enno Schmidt Klinik für Dermatologie, Allergologie und Venerologie Lübecker Institut für Experimentelle Dermatologie (LIED) Universität Lübeck Ratzeburger Allee 160 23562 Lübeck E-mail: [email protected]Search for more papers by this authorMatthias Goebeler, Matthias Goebeler Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, WürzburgSearch for more papers by this authorMichael Hertl, Michael Hertl Klinik für Dermatologie und Allergology Universitätsklinikum MarburgSearch for more papers by this authorMiklós Sárdy, Miklós Sárdy Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München (LMU), MünchenSearch for more papers by this authorCassian Sitaru, Cassian Sitaru Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, FreiburgSearch for more papers by this authorRüdiger Eming, Rüdiger Eming Klinik für Dermatologie und Allergology Universitätsklinikum MarburgSearch for more papers by this authorSilke C. Hofmann, Silke C. Hofmann Zentrum für Dermatologie, Allergologie und Dermatochirurgie, Helios Klinikum WuppertalSearch for more papers by this authorNicolas Hunzelmann, Nicolas Hunzelmann Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu KölnSearch for more papers by this authorJohannes S. Kern, Johannes S. Kern Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, FreiburgSearch for more papers by this authorHarald Kramer, Harald Kramer Niedergelassener Dermatologe, FuldaSearch for more papers by this authorHans-Dieter Orzechowski, Hans-Dieter Orzechowski Institut für Klinische Pharmakologie und Toxikologie, Charité - Universitätsmedizin BerlinSearch for more papers by this authorChristiane Pfeiffer, Christiane Pfeiffer Klinik für Dermatologie und Allergologie, Universitätsklinikum UlmSearch for more papers by this authorVolker Schuster, Volker Schuster Pädiatrische Immunologie und Rheumatologie, Universitätsklinik und Poliklinik für Kinder und Jugendliche, LeipzigSearch for more papers by this authorBirte Sporbeck, Birte Sporbeck Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this authorMichael Sticherling, Michael Sticherling Hautklinik, Universitätsklinikum Erlangen, ErlangenSearch for more papers by this authorMargitta Worm, Margitta Worm Allergie-Centrum, Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this authorDetlef Zillikens, Detlef Zillikens Klinik für Dermatologie, Allergologie und Venerologie, Universität Lübeck, LübeckSearch for more papers by this authorAlexander Nast, Alexander Nast Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this author Enno Schmidt, Corresponding Author Enno Schmidt Klinik für Dermatologie, Allergologie und Venerologie, Universität Lübeck, Lübeck Korrespondenzanschrift Prof. Dr. med. Dr. rer. nat. Enno Schmidt Klinik für Dermatologie, Allergologie und Venerologie Lübecker Institut für Experimentelle Dermatologie (LIED) Universität Lübeck Ratzeburger Allee 160 23562 Lübeck E-mail: [email protected]Search for more papers by this authorMatthias Goebeler, Matthias Goebeler Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, WürzburgSearch for more papers by this authorMichael Hertl, Michael Hertl Klinik für Dermatologie und Allergology Universitätsklinikum MarburgSearch for more papers by this authorMiklós Sárdy, Miklós Sárdy Klinik und Poliklinik für Dermatologie und Allergologie, Klinikum der Universität München (LMU), MünchenSearch for more papers by this authorCassian Sitaru, Cassian Sitaru Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, FreiburgSearch for more papers by this authorRüdiger Eming, Rüdiger Eming Klinik für Dermatologie und Allergology Universitätsklinikum MarburgSearch for more papers by this authorSilke C. Hofmann, Silke C. Hofmann Zentrum für Dermatologie, Allergologie und Dermatochirurgie, Helios Klinikum WuppertalSearch for more papers by this authorNicolas Hunzelmann, Nicolas Hunzelmann Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu KölnSearch for more papers by this authorJohannes S. Kern, Johannes S. Kern Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, FreiburgSearch for more papers by this authorHarald Kramer, Harald Kramer Niedergelassener Dermatologe, FuldaSearch for more papers by this authorHans-Dieter Orzechowski, Hans-Dieter Orzechowski Institut für Klinische Pharmakologie und Toxikologie, Charité - Universitätsmedizin BerlinSearch for more papers by this authorChristiane Pfeiffer, Christiane Pfeiffer Klinik für Dermatologie und Allergologie, Universitätsklinikum UlmSearch for more papers by this authorVolker Schuster, Volker Schuster Pädiatrische Immunologie und Rheumatologie, Universitätsklinik und Poliklinik für Kinder und Jugendliche, LeipzigSearch for more papers by this authorBirte Sporbeck, Birte Sporbeck Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this authorMichael Sticherling, Michael Sticherling Hautklinik, Universitätsklinikum Erlangen, ErlangenSearch for more papers by this authorMargitta Worm, Margitta Worm Allergie-Centrum, Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this authorDetlef Zillikens, Detlef Zillikens Klinik für Dermatologie, Allergologie und Venerologie, Universität Lübeck, LübeckSearch for more papers by this authorAlexander Nast, Alexander Nast Division of Evidence Based Medicine (dEBM), Klinik für Dermatologie, Charité – Universitätsmedizin BerlinSearch for more papers by this author First published: 25 June 2015 https://doi.org/10.1111/ddg.40_12612Citations: 39Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Literatur 1Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) - Ständige Komission Leitlinien. AWMF-Regelwerk "Leitlinien". 1. Auflage Edition, 2012. 2Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol. 1982; 62: 491–6. 3Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009; 161: 861–8. 4Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007; 46: 356–61. 5Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, Barzegari M, Akhiani M, Ghodsi Z, Mortazavi H, Naraghi Z. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005; 44: 470–6. 6Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, Ciuce D, Sitaru C. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010; 49: 768–74. 7Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol. 1974; 38: 382–7. 8Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol. 1980; 116: 1035–7. 9Hahn-Ristic K, Rzany B, Amagai M, Brocker EB, Zillikens D. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J Eur Acad Dermatol Venereol. 2002; 16: 68–71. 10Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges. 2011; 9: 844–56; quiz 57. 11Schmidt E, Zillikens D. The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int. 2011; 108: 399–405. 12Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology. 2009; 218: 237–45. 13Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009; 129: 2404–10. 14Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Hall R, Harman KE, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman MF, Kitajima Y, Korman NJ, Martin LK, Mimouni D, Pandya AG, Payne AS, Rubenstein D, Shimizu H, Sinha AA, Sirois D, Zillikens D, Werth VP. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008; 58: 1043–6. 15Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H, 3rd, Mutasim D, Ariss-Abdo L, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323: 1729–35. 16Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges. 2011; 9: 927–47. 17Sabolinski ML, Beutner EH, Krasny S, Kumar V, Huang J, Chorzelski TP, Sampaio S, Bystryn JC. Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. J Invest Dermatol. 1987; 88: 545–9. 18Jiao D, Bystryn JC. Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. J Am Acad Dermatol. 1997; 37: 211–6. 19Jarzabek-Chorzelska M, Strasz-Kolacinska Z, Sulej J, Jablonska S. The use of two substrates for indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol. 2001; 145: 178–82. 20Harman KE, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus. Br J Dermatol. 2000; 142: 1135–9. 21Hahn K, Kippes W, Amagai M, Rzany B, Brocker EB, Zillikens D. [Clinical aspects and immunopathology in 48 patients with pemphigus]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2000; 51: 670–7. 22Zagorodniuk I, Weltfriend S, Shtruminger L, Sprecher E, Kogan O, Pollack S, Bergman R. A comparison of anti-desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of pemphigus vulgaris. International journal of dermatology. 2005; 44: 541–4. 23Ahmed AR, Workman S. Anti-intercellular substance antibodies. Presence in serum samples of 14 patients without pemphigus. Arch Dermatol. 1983; 119: 17–21. 24Goldblatt F, Gordon TP. Antibodies to blood group antigens mimic pemphigus staining patterns: a useful reminder. Autoimmunity. 2002; 35: 93–6. 25Lee FJ, Silvestrini R, Fulcher DA. False-positive intercellular cement substance antibodies due to group A/B red cell antibodies: frequency and approach. Pathology. 2010; 42: 574–7. 26Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997; 159: 2010–7. 27Schmidt E, Dahnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stocker W, Hashimoto T, Brocker EB, Recke A, Rose C, Zillikens D. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol. 2010; 19: 458–63. 28vanBeek N, Rentzsch K, Probst C, Komorowski L, Kasperkiewicz M, Fechner K, Bloecker IM, Zillikens D, Stocker W, Schmidt E. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet journal of rare diseases. 2012; 7: 49. 29Tampoia M, Zucano A, Villalta D, Antico A, Bizzaro N. Anti-skin specific autoantibodies detected by a new immunofluorescence multiplex biochip method in patients with autoimmune bullous diseases. Dermatology. 2012; 225: 37–44. 30Zarian H, Saponeri A, Michelotto A, Zattra E, Belloni-Fortina A, Alaibac M. Biochip technology for the serological diagnosis of bullous pemphigoid. ISRN Dermatol. 2012; 2012: 237802. 31Tampoia M, Giavarina D, Di Giorgio C, Bizzaro N. Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis. Autoimmun Rev. 2012; 12: 121–6. 32Muller R, Svoboda V, Wenzel E, Muller HH, Hertl M. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Experimental dermatology. 2008; 17: 35–43. 33Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999; 40: 167–70. 34Ding X, Aoki V, Mascaro JM, Jr., Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997; 109: 592–6. 35Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999; 103: 461–8. 36Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol. 2000; 25: 236–40. 37Lenz P, Amagai M, Volc-Platzer B, Stingl G, Kirnbauer R. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Arch Dermatol. 1999; 135: 143–8. 38Ng PP, Thng ST, Mohamed K, Tan SH. Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus. Australas J Dermatol. 2005; 46: 239–41. 39Bystryn JC, Akman A, Jiao D. Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus. Arch Dermatol. 2002; 138: 1252–3. 40Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem. 2000; 275: 29466–76. 41Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol. 2000; 157: 1377–91. 42Cozzani E, Dal Bello MG, Mastrogiacomo A, Drosera M, Parodi A. Antidesmoplakin antibodies in pemphigus vulgaris. Br J Dermatol. 2006; 154: 624–8. 43Evangelista F, Dasher DA, Diaz LA, Prisayanh PS, Li N. E-cadherin is an additional immunological target for pemphigus autoantibodies. J Invest Dermatol. 2008; 128: 1710–8. 44Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012; 45: 7–35. 45Muller R, Heber B, Hashimoto T, Messer G, Mullegger R, Niedermeier A, Hertl M. Autoantibodies against desmocollins in European patients with pemphigus. Clinical and experimental dermatology. 2009; 34: 898–903. 46Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004; 9: 29–33. 47Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, Beylot-Barry M, D'Incan M, Martel P, Lauret P, Tron F. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000; 43: 619–26. 48Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007; 34: 503–11. 49Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010; 8: 598–605. 50Kim SC, Kwon YD, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol. 1997; 109: 365–9. 51Probst C, Schlumberger W, Stocker W, Recke A, Schmidt E, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta. 2009; 410: 13–8. 52Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol. 1998; 111: 308–13. 53Schepens I, Jaunin F, Begre N, Laderach U, Marcus K, Hashimoto T, Favre B, Borradori L. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One. 2010; 5: e12250. 54Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998; 102: 775–82. 55Ruocco V, Pisani M. Induced pemphigus. Arch Dermatol Res. 1982; 274: 123–40. 56Wolf R, Tamir A, Brenner S. Drug-induced versus drug-triggered pemphigus. Dermatologica. 1991; 182: 207–10. 57Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998; 16: 393–7. 58Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titers in pemphigus. Arch Dermatol. 1980; 116: 285–90. 59Abasq C, Mouquet H, Gilbert D, Tron F, Grassi V, Musette P, Joly P. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009; 145: 529–35. 60Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002; 147: 261–5. 61Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001; 144: 775–80. 62Bastuji-Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, Roujeau JC, Bernard P, Guillaume JC, Ingen-Housz-Oro S, Maillard H, Pauwels C, Picard-Dahan C, Dutronc Y, Richard MA, French Study Group for Bullous D. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. The Journal of investigative dermatology. 2011; 131: 637–43. 63Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, Salagnac V, Lok C, Roujeau JC. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996; 132: 272–6. 64Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013; 149: 58–62. 65Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, Hwang CY, Chu SY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011; 165: 593–9. 66Cordel N, Chosidow O, Hellot MF, Delaporte E, Lok C, Vaillant L, Bernard P, D'Incan M, Roujeau JC, Joly P. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007; 215: 187–91. 67Cortes B, Marazza G, Naldi L, Combescure C, Borradori L. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol. 2011; 165: 368–74. 68Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases - A case-control study. Eur J Dermatol. 2010; 20: 96–101. 69Kulthanan K, Chularojanamontri L, Tuchinda P, Sirikudta W, Pinkaew S. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol. 2011; 29: 66–72. 70Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. The Journal of investigative dermatology. 2011; 131: 631–6. 71Taghipour K, Chi CC, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol. 2010; 146: 1251–4. 72Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha AA, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman MF, Pandya AG, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM, Jr., Schmidt E, Shimizu H, Zone J, Swerlick R, Mimouni D, Culton D, Lipozencic J, Bince B, Grando SA, Bystryn JC, Werth VP. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. Journal of the American Academy of Dermatology. 2012; 66: 479–85. 73Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmunity reviews. 2010; 10: 84–9. 74Terra JB, Pas HH, Hertl M, Dikkers FG, Kamminga N, Jonkman MF. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol. 2011; 165: 815–22. 75Vodegel RM, Jonkman MF, Pas HH, deJong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004; 151: 112–8. 76Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990; 22: 664–70. 77Rose C, Schmidt E, Kerstan A, Thoma-Uszynski S, Wesselmann U, Kasbohrer U, Zillikens D, Shimanovich I. Histopathology of anti-laminin 5 mucous membrane pemphigoid. Journal of the American Academy of Dermatology. 2009; 61: 433–40. 78Rose C, Weyers W, Denisjuk N, Hillen U, Zillikens D, Shimanovich I. Histopathology of anti-p200 pemphigoid. Am J Dermatopathol. 2007; 29: 119–24. 79Gammon WR, Briggaman RA, Inman AO, 3rd, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol. 1984; 82: 139–44. 80Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol. 1988; 118: 31–40. 81Ghohestani R, Kanitakis J, Nicolas JF, Cozzani E, Claudy A. Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Br J Dermatol. 1996; 135: 74–9. 82Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol. 1997; 133: 1102–7. 83Chan YC, Sun YJ, Ng PP, Tan SH. Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid. Clin Exp Dermatol. 2003; 28: 651–6. 84Kippes W, Schmidt E, Roth A, Rzany B, Brocker EB, Zillikens D. [Immunopathologic changes in 115 patients with bullous pemphigoid]. Hautarzt. 1999; 50: 866–72. 85Sardy M, Kostaki D, Varga R, Peris K, Ruzicka T. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. Journal of the American Academy of Dermatology. 2013; 69: 748–53. 86vanBeek N, Dohse A, Riechert F, Krull V, Recke A, Zillikens D, Schmidt E. Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited. Br J Dermatol. 2014; 170: 943–7. 87Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WL, Lever WF. Basement zone antibodies in bullous pemphigoid. Jama. 1967; 200: 751–6. 88Beutner EH, Jordon RE, Chorzelski TP. The immunopathology of pemphigus and bullous pemphigoid. J Invest Dermatol. 1968; 51: 63–80. 89Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013; 381: 320–32. 90Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993; 151: 5742–50. 91Zillikens D, Rose PA, Balding SD, Liu Z, Olague-Marchan M, Diaz LA, Giudice GJ. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol. 1997; 109: 573–9. 92Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K, Nishikawa T. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002; 30: 224–32. 93Sitaru C, Dahnrich C, Probst C, Komorowski L, Blocker I, Schmidt E, Schlumberger W, Rose C, Stocker W, Zillikens D. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol. 2007; 16: 770–7. 94Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K, Imamura K, Okamoto E, Yasumoto S, Hashimoto T. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci. 2006; 41: 21–30. 95Blocker IM, Dahnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stocker W, Zillikens D, Schmidt E. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Br J Dermatol. 2012; 166: 964–70. 96Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C, Tabary T, Grange F, Bernard P. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol. 2011; 147: 286–91. 97Tampoia M, Lattanzi V, Zucano A, Villalta D, Filotico R, Fontana A, Vena GA, Di Serio F. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci. 2009; 1173: 15–20. 98Roussel A, Benichou J, Randriamanantany ZA, Gilbert D, Drenovska K, Houivet E, Tron F, Joly P. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol. 2011; 147: 293–8. 99Wieland CN, Comfere NI, Gibson LE, Weaver AL, Krause PK, Murray JA. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol. 2010; 146: 21–5. 100della Torre R, Combescure C, Cortes B, Marazza G, Beltraminelli H, Naldi L, Borradori L. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012; 167: 1111–7. 101Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol. 2007; 23: 257–88. 102Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin. 2011; 29: 427–38, viii-ix. 103Korman N. Bullous pemphigoid. J Am Acad Dermatol. 1987; 16: 907–24. 104Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, Hoang-Xuan T, Kirtschig G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS, 3rd, Setterfield JF, West DP, Wojnarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002; 138: 370–9. 105Di Zenzo G, Calabresi V, Grosso F, Caproni M, Ruffelli M, Zambruno G. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol. 2007; 127: 864–73. 106Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour JP, Wieslander J, Bruckner-Tuderman L, Borradori L, Zambruno G, Hertl M. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008; 128: 415–26. 107vanBeek N, Knuth-Rehr D, Altmeyer P, Assaf C, Babilas P, Bayerl C, Benoit S, Dippel E, Effendy I, Eming R, Fischer M, Glaenz T, Glaser R, Goebeler M, Gollnick H, Gotze S, Gross G, Hadaschik E, Herbst R, Hermes B, Homey B, Hunzelmann N, Junger M, Kapp A, Kern JS, Korber A, Luger T, Mechtel D, Megahed M, Moll I, Peters KP, Pfeiffer C, Ring J, Rocken M, Sardy M, Seitz CS, Stadler R, Steinbrink K, Sticherling M, Szeimies RM, Tronnier M, Ulrich J, Vogt T, Wagner N, Welzel J, Wenzel J, Wozel G, Zouboulis CC, Zillikens D, Schmidt E. Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges. 2012; 10: 492–9. 108Komorowski L, Muller R, Vorobyev A, Probst C, Recke A, Jonkman MF, Hashimoto T, Kim SC, Groves R, Ludwig RJ, Zillikens D, Stocker W, Schmidt E. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. Journal of the American Academy of Dermatology. 2013; 68: e89-95. 109Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, Schmidt E, Zillikens D, Shirakata Y, Hashimoto K, Kitajima Y, Amagai M. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci. 2011; 62: 169–75. 110Lindelof B, Islam N, Eklund G, Arfors L. Pemphigoid and cancer. Arch Dermatol. 1990; 126: 66–8. 111Ogawa H, Sakuma M, Morioka S, Kitamura K, Sasai Y, Imamura S, Inaba Y. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995; 9: 136–41. 112Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre M. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res. 2014; 306: 75–80. 113Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol. 2015; 135: 1445–7. 114Amo Y, Ohkawa T, Tatsuta M, Hamada Y, Fujimura T, Katsuoka K, Hashimoto T. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2001; 26: 14–8. 115Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000; 136: 174–8. 116Pas HH, deJong MC, Jonkman MF, Heeres K, Slijper-Pal IJ, vander Meer JB. Bullous pemphigoid: serum antibody titre and antigen specificity. Exp Dermatol. 1995; 4: 372–6. 117Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol. 2011; 131: 2271–80. Citing Literature Volume13, Issue7July 2015Pages 713-727 ReferencesRelatedInformation
Referência(s)